The simple benefit to PNV is that the method can be used on a vast number of people. There are circa 8.4 m T1D people world wide. That is a lot of potential Novosorb BTM use. Lets say they access 10% of the market per year to get the beta cell treatment with say $800 worth of BTM. That would be around 670 million dollars worth of product
PNV Price at posting:
$1.48 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)